pH/ROS-Responsive Injectable Hydrogel Co-Loaded with B7-H3 Blocker and NETs Suppressor Boosts OSCC Synergistic Immunotherapy - PubMed
8 days ago
- #immunotherapy
- #OSCC
- #hydrogel
- Injectable pH/ROS-responsive hydrogel co-loaded with B7-H3 blocker (enoblituzumab) and NETs suppressor (Cl-amidine) for OSCC immunotherapy.
- Hydrogel formed by boronic ester bonds and Schiff base linkages ensures precise drug release in acidic, high-ROS tumor microenvironment (TME).
- Localized intratumoral delivery avoids systemic toxicity and off-target effects, enabling high intratumoral drug accumulation.
- Significant tumor growth suppression in orthotopic and subcutaneous OSCC models compared to monotherapies or controls.
- Synergistic TME reprogramming: Cl-amidine inhibits NETs to enhance T-cell infiltration, enoblituzumab restores cytotoxic T-cell function and boosts antibody-dependent cellular cytotoxicity.
- Suppression of OSCC invasion and metastasis by inhibiting B7-H3 and NETs, reversing epithelial-mesenchymal transition (EMT).
- Excellent biocompatibility with no systemic toxicity observed.